Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

Thumbnail

Edwards shares ‘encouraging’ 5-year data on RESILIA tissue aortic valve

According to new data from the ongoing COMMENCE clinical trial, patients showed no signs of structural valve deterioration after five years.

Thumbnail

CMS expands Medicare coverage for TMVR, now known as TEER, to include patients with functional MR

Abbott described the update as "critically important," and the American College of Cardiology expressed relief that some proposed changes did not actually end up happening. 

Thumbnail

TAVR in the time of COVID-19: Providers quickly adapted, delivering ‘excellent’ outcomes

Researchers compared patient outcomes from 2019 with data from the pandemic’s first four months, sharing their findings in the American Journal of Cardiology.  

Thumbnail

No reason to quit: TAVR patients can continue anticoagulation therapy throughout procedure

Patients are typically told to put anticoagulation therapy on hold two to four days before they undergo TAVR. This study’s authors aimed to see if this was truly necessary.  

Thumbnail

CKD patients on dialysis face worse TAVR outcomes, including a higher risk of in-hospital mortality

The authors examined data from more than 42,000 patients who received care from 2012 to 2017. 

Thumbnail

FDA announces new recall for extended-release metformin due to contamination

Numerous recalls for ER metformin occurred in 2020. This is the first of 2021.

Thumbnail

In-hospital stroke rates higher after TAVR than MitraClip procedures

Post-discharge stroke rates, however, were similar between the two procedures.

Thumbnail

Edwards evaluating the safety, effectiveness of new mitral valve repair solution

The system was designed to require only one small incision to repair a patient’s mitral valve. 

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.